End stage renal disease patients on hemodialysis. End stage kidney disease:on dialysis
Conditions
Interventions
Intervention 1: Intervention /group A
Supplementation with cholecalciferol will be done in 25 hydoxyvitamin D deficiency 35 patients on thrice weekly maintenence hemodialysis patients according to 25-
Treatment - Drugs
Placebo
Intervention /group A
Supplementation with cholecalciferol will be done in 25 hydoxyvitamin D deficiency 35 patients on thrice weekly maintenence hemodialysis patients according to 25-hydroxyvitamin
Control group/Group BSimilar placebo is given to group B patients on thrice weekly maintenance hemodialysis patients according to 25-hydroxyvitamin D levels . The supplementation with placebo, once a
Sponsors
Nephrology Department, Shaikh Zayad Hospital
Shaikh Zayad Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age more than 18 years On hemodialysis thrice per week for more than 3 months Both the gender Patients who give informed consents Exclusion criteria: The patients with history of active bleeding (melena, hematemesis, hematochezia). Patients who have taken cholecalceferol or ergocholicalciferol within two months period, Patients taking cinacalcet Iv Iron in 1 month prior to enrollment Blood transfusion 1month prior to enrollment during the study Any diagnosed malignancy, tubercular infection, sarcoidosis, pregnancy Calcitriol or active vitamin D3 or erythropoietin dosage adjustment 1 month prior to enrollment Patients having corrected serum calcium>10.2 mg/dl or having serum phosphorus >6mg/dl
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. 25 hydroxyvitamin D level. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA kit.;2. intact Parathyroid Hormone (iPTH). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA kit.;3. Alkaline Phosphatase. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;4. Calcium (Ca). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;5. Phosphorus (P). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Standard chemical analyzer.;6. calcium phosphorus product(Ca x P). Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: calculated from calcium and phosphorus product. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. C Reactive Protein. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: ELISA Kit.;2. Chronic musculoskeletal symptoms. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Visual Analog Scale.;3. White blood cell count. Timepoint: At baseline and 2 months after the date of intervention. Method of measurement: Automated counter. | — |
Countries
Pakistan
Contacts
Public ContactSumit Acharya
College of Physician and Surgeon of Pakistan
Outcome results
None listed